Literature DB >> 28412046

The epigenetic mechanism for discordance of autoimmunity in monozygotic twins.

Zhongyuan Xiang1, Yuanqing Yang1, Christopher Chang2, Qianjin Lu3.   

Abstract

Monozygotic twins share an identical DNA sequence but are not truly "identical". In fact, when it comes to health and disease, they may often display some level of phenotypic discordance. The cause of this discordance is often unknown. Epigenetic modifications such as DNA methylation, histone modification, and microRNAs-mediated regulation regulate gene expression and are sensitive to external stimuli. These modifications may be seen to bridge the gap between genetics and the environment. Over the years, the importance of epigenetics as a primary mechanism for the role that the environment plays in defining phenotype has been increasingly appreciated. Mechanisms of epigenetics include DNA methylation, histone modifications and microRNAs. Discordance rates in monozygotic twins vary depending on the specific condition, from 11% in SLE to 64% in psoriasis and 77% in PBC. Other autoimmune diseases in which discordance is found among monozygotic twins has also been studied include type 1 diabetes, multiple sclerosis, rheumatoid arthritis, dermatomyositis and systemic sclerosis. In some cases, the differences in various epigenetic modifications is slight, even though the concordance rate is low, suggesting that epigenetics is not the only factor that needs to be considered. Nonetheless, the study of phenotypic discordance in monozygotic twins may shed light on the pathogenesis of autoimmune diseases and contribute to the development of new methodologies for the diagnosis and treatment of these diseases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmune diseases; DNA methylation; Epigenetics; Histone modification; MicroRNAs-mediated regulation; Monozygotic twin

Mesh:

Substances:

Year:  2017        PMID: 28412046     DOI: 10.1016/j.jaut.2017.04.003

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  26 in total

Review 1.  Environmental basis of primary biliary cholangitis.

Authors:  Atsushi Tanaka; Patrick Sc Leung; M Eric Gershwin
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-07

2.  Translational Opportunities for Microfluidic Technologies to Enable Precision Epigenomics.

Authors:  Yi Xu; Steven R Doonan; Tamas Ordog; Ryan C Bailey
Journal:  Anal Chem       Date:  2020-06-04       Impact factor: 6.986

Review 3.  Primary biliary cholangitis: a comprehensive overview.

Authors:  Ana Lleo; Simona Marzorati; Juan-Manuel Anaya; M Eric Gershwin
Journal:  Hepatol Int       Date:  2017-11-21       Impact factor: 6.047

4.  The long and latent road to autoimmunity.

Authors:  Carlo Selmi; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2018-03-22       Impact factor: 11.530

Review 5.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 6.  Intratumoral Heterogeneity: More Than Just Mutations.

Authors:  Kunihiko Hinohara; Kornelia Polyak
Journal:  Trends Cell Biol       Date:  2019-04-12       Impact factor: 20.808

7.  Exposure to Environmental Toxins and Autoimmune Conditions.

Authors:  Datis Kharrazian
Journal:  Integr Med (Encinitas)       Date:  2021-04

8.  Aberrant hydroxymethylation of ANGPTL4 is associated with selective intrauterine growth restriction in monochorionic twin pregnancies.

Authors:  Yi Zhang; Dezhong Zheng; Qun Fang; Mei Zhong
Journal:  Epigenetics       Date:  2020-03-05       Impact factor: 4.528

Review 9.  Epigenetics of inflammatory arthritis.

Authors:  Deepa Hammaker; Gary S Firestein
Journal:  Curr Opin Rheumatol       Date:  2018-03       Impact factor: 5.006

Review 10.  Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review.

Authors:  Benedetta Terziroli Beretta-Piccoli; Pietro Invernizzi; M Eric Gershwin; Carlo Mainetti
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.